Five Observations From the 2017 Fair Pricing Forum

Posted by Ed Schoonveld on Mon, May 15, 2017

In May, I joined various members of governmental organizations, patient organizations and the life sciences industry at the 2017 Fair Pricing Forum, an invitation-only meeting to discuss “fair pricing” for medications in Amsterdam. Organized by the World Health Organization and the Dutch Ministry of Health, the meeting prompted a productive dialogue among stakeholders but also revealed a worrisome gap in the overall perception of the drug pricing discussion. The pharmaceutical industry’s viewpoint was widely underrepresented, with attendance heavily weighted toward governments and activists, and only a small industry delegation.


>
Read More

Is the FDA Stepping Into the 21st Century?

Posted by Ed Schoonveld on Wed, Mar 22, 2017


Until recently, the pharmaceutical industry has been severely limited in its ability to communicate with customers regarding the economic impact of new drug treatments. Under the 21st Century Cures Act, which was approved with broad bipartisan support and signed by then-President Barack Obama in December 2016, the pharmaceutical industry has a much broader mandate to discuss healthcare economic information with payers and formulary decision makerswith some fairly reasonable requirements.


>
Read More

US Drug Pricing: Pushing Beyond Soundbites to Offer Real Solutions

Posted by Ed Schoonveld on Wed, Mar 15, 2017

Drug pricing is a recurring topic amongst U.S. politicians and the media, and it experiences the occasional erratic peak in attention when President Trump aims his early morning tweets at pharma. It’s a much more complex topic than can be discussed in 140 characters, however, and unfortunately, the pharmaceutical industry thus far hasn’t been able to provide compelling answers to politicians and the public. Some bad actors, such as Turings’s ex-CEO Martin Shkreli, have seriously harmed the industry’s reputation, and pharmaceutical companies now need to act.


>
Read More

Obamacare’s Repeal: What to Expect

Posted by Ed Schoonveld on Mon, Jan 16, 2017

 
It has been difficult to predict what repealing and replacing the Affordable Care Act (ACA), the signature legislation from President Barack Obama, will mean for the public and for the insurance and pharmaceutical industries. The lack of Republican consensus behind a single alternative plan and the uncertainty of President-elect Donald Trump’s actions have turned any projection into mere speculation. However, recent Republican steps and political reality are now starting to help clarify what the likely outcome of “repeal and replace” may be.


>
Read More

Brexit’s Impact on the EU’s Drug-Pricing Climate

Posted by Ed Schoonveld on Thu, Jun 30, 2016


Surprised and stunned by the U.K’s vote last Friday to exit the European Union, the world is experiencing a collective panic. However, currency and stock devaluations have mainly been driven by uncertainty rather than solid projections of corporate performance gaps, all of which has been further enhanced and inflamed by the media in their constant quest for better ratings.


>
Read More